PB0854 - Evaluation of the hemostatic ability of the new device Total Thrombus Formation Analysis System’ (T-TAS) for thrombocytopenic patients. In vitro effect of Thrombosomes®

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

SS

Sahar Samanbar

Technical Research Assistant
Hematopathology, Pathology Department, CDB, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Barcelona, Catalonia, Spain
Ana Belén Moreno-Castaño, MD

Medical Doctor
Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Barcelona, Catalonia, Spain
JP

Juan Piñeyroa

Medical Doctor
Hematology Department, Hospital Clinic, Barcelona, Spain
Barcelona, Catalonia, Spain
MP

Marc Pino

Laboratory Technician
Hemostasis and Erythropatology Laboratory, Pathology Department, CDB
Barcelona, Catalonia, Spain
ST

Sergi Torramade-Moix

PhD
Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Barcelona, Catalonia, Spain
Julia Martinez-Sanchez, MS

PhD student
Josep Carreras Leukaemia Research Institute, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
Barcelona, Catalonia, Spain
KM

Keith Moskowitz

VP of discovery
Cellphire Therapeutics, Inc., Rockville, MD, USA
Rockville, Maryland, United States
GE

Gines Escolar

MD PhD Senior Consultant
Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Barcelona, Catalonia, Spain

Presenting Author(s)

Maribel Diaz-Ricart, PhD

Senior Researcher
Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Barcelona, Catalonia, Spain

Background: Bleeding complications in thrombocytopenic patients constitute a significant problem in clinical practice. Current laboratory approaches fail to evaluate hemostasis in thrombocytopenia and also the efficacy of platelet transfusion. The Total Thrombus Formation Analysis System (T-TAS) is a new approach proposed to explore hemostasis in samples with low platelet counts. T-TAS may become an alternative tool to explore the hemostatic effect of hemoderivatives.

Aims: To validate T-TAS as a suitable device to evaluate hemostasis in samples from thrombocytopenic patients before and after platelet transfusion. To explore the hemostatic efficiency of in vitro addition of Thrombosomes®, a human platelet-derived lyophilized hemostatic agent proposed for the treatment of bleeding in thrombocytopenia.

Methods: Whole blood from hematological thrombocytopenic patients (n=28) (platelet count < 30x10^3 platelets/µl) was collected before and after platelet transfusion. Hemostasis was evaluated through T-TAS, with specific chips (HD) containing microcapillary channels (50-μm-deep) coated with collagen and tissue factor. Area under the curve (AUC) and occlusion times (OT, min) were registered for both samples before and after addition of Thrombosomes® (50x10^3/µl).

Results: Values (Mean±SEM) of platelet counts were of 10±1.2 and 24±2 (x10^3 platelets/µl) and hematocrits (HCT) were of 24±0.6% and 27±1%, before and after platelet transfusion, respectively. T-TAS demonstrated significant improvements after platelet transfusion (see Table 1). Addition of Thrombosomes® increased AUC and shortened OT in 60% and 100% of samples from non-transfused (p˂0.05) and transfused patients, respectively.

Conclusion(s): The newly designed system T-TAS, using a modified microchip-based flow chamber, was able to measure hemostasis in samples with thrombocytopenia and low hematocrit. T-TAS was useful to evaluate the hemostatic capacity of transfused platelets. Moreover, T-TAS offers a platform to assess the hemostatic effect of hemoderivatives, such as Thrombosomes®, which enabled hemostasis even in those samples in which it was severely impaired.